AstraZeneca and second dose with vaccine mix, ministry circular

AstraZeneca and second dose, on the mix of vaccines comes the circular of the Ministry of Health after the green light of Aifa for administration in Italy. With a circular signed by the Director General for Prevention Gianni Rezza, in fact, the Ministry of Health transmitted the decision of the Director General of the Italian Medicines Agency Aifa, Nicola Magrini, and the opinion of the Technical Scientific Commission of the national regulatory body, on the matter. the use of the anti-Covid Comirnaty * (Pfizer / BioNTech) and Moderna vaccines in a mixed vaccination schedule (heterologous vaccination), in subjects under the age of 60 who have already taken a first dose with Vaxzevria * (AstraZeneca) vaccine. Read also The green light Aifa “The Technical Scientific Commission (Cts) of the Italian Medicines Agency Aifa, in the meeting of 13 June last, expressed its opinion on how to use the mixed vaccination schedule in subjects under 60 years of age who received a first dose of Vaxzevria * vaccine “, AstraZeneca’s anti-Covid,” also in consideration of the changed epidemiological scenario of reduced viral circulation. The AIFA announced this last night, explaining that, “on the basis of clinical studies published in recent weeks, the CTS has decided, in the face of a significant enhancement of the antibody response and a good reactogenicity profile, to approve the vaccine mix: first dose with Vaxzevria and second dose with Comirnaty * “, the vaccine from Pfizer / BioNTech” or, by analogy, with the Moderna vaccine “. “In consideration of the evidence that has just become available, of the current absence of specific indications in the Summary of Product Characteristics (Rcp) of the drugs in question and the need to allow the vaccination campaign to run smoothly”, Aifa has therefore expressed “favorable opinion for the inclusion in the list of drugs referred to in the law 648/1996 of Comirnaty and Vaccino Covid-19 Moderna as a second dose to complete a mixed vaccination cycle, in subjects under the age of 60 who have already undergone a first dose of Vaxzevria vaccine “. The CTS considered that the second administration with the mRna vaccine could take place “8-12 weeks after the administration of Vaxzevria. It is currently being published in the Official Gazette – the AIFA informed yesterday – the implementation determination”.